Teva unseats Pfizer
Based on prescriptions dispensed, Teva has become the top pharmaceutical company in the U.S. following its merger with Ivax. Pro-forma 2005 numbers from IMS put the combined company at 364 mil. annual scripts, versus 324 mil. for previously number one Pfizer, which is starting to emphasize its fast-growing Greenstone generic business (1"The Pink Sheet" Feb. 20, 2006, p. 21). In terms of sales, Teva will be the 14th largest pharma company in the U.S. The company expects the $7.4 bil. acquisition will aid its geographic expansion and price negotiations (2"The Pink Sheet" Aug. 1, 2005, p. 19)...
You may also be interested in...
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.